Sawitzki B, Harden PN, Reinke P et al (2020) Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet 395:1627–1639. https://doi.org/10.1016/S0140-6736(20)30167-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harden PN, Game DS, Sawitzki B et al (2021) Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients. Am J Transplant 21:1603–1611. https://doi.org/10.1111/ajt.16395

Article  CAS  PubMed  PubMed Central  Google Scholar 

Whangbo JS, Nikiforow S, Kim HT et al (2022) A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease. Blood Adv 6:5786–5796. https://doi.org/10.1182/bloodadvances.2021006625

Article  CAS  PubMed  PubMed Central  Google Scholar 

Desreumaux P, Foussat A, Allez M et al (2012) Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn’s disease. Gastroenterology 143(1207–1217):e1202. https://doi.org/10.1053/j.gastro.2012.07.116

Article  CAS  Google Scholar 

Chaudhry D, Chaudhry A, Peracha J, Sharif A (2022) Survival for waitlisted kidney failure patients receiving transplantation versus remaining on waiting list: systematic review and meta-analysis. BMJ 376:e068769. https://doi.org/10.1136/bmj-2021-068769

Article  PubMed  PubMed Central  Google Scholar 

Axelrod DA, Schnitzler MA, Xiao H et al (2018) An economic assessment of contemporary kidney transplant practice. Am J Transplant 18:1168–1176. https://doi.org/10.1111/ajt.14702

Article  PubMed  Google Scholar 

Sellares J, de Freitas DG, Mengel M et al (2012) Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 12:388–399. https://doi.org/10.1111/j.1600-6143.2011.03840.x

Article  CAS  PubMed  Google Scholar 

Mikami N, Sakaguchi S (2023) Regulatory T cells in autoimmune kidney diseases and transplantation. Nat Rev Nephrol 19:544–557. https://doi.org/10.1038/s41581-023-00733-w

Article  CAS  PubMed  Google Scholar 

Fraser H, Safinia N, Grageda N et al (2018) A rapamycin-based GMP-compatible process for the isolation and expansion of regulatory T cells for clinical trials. Mol Ther Methods Clin Dev 8:198–209. https://doi.org/10.1016/j.omtm.2018.01.006

Article  CAS  PubMed  PubMed Central  Google Scholar 

Balcerek J, Shy BR, Putnam AL et al (2021) Polyclonal regulatory T cell manufacturing under cGMP: a decade of experience. Front Immunol 12:744763. https://doi.org/10.3389/fimmu.2021.744763

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mathew JM, J HV, LeFever A et al (2018) A phase I clinical trial with ex vivo expanded recipient regulatory T cells in living donor kidney transplants. Sci Rep 8:7428. https://doi.org/10.1038/s41598-018-25574-7

Roemhild A, Otto NM, Moll G et al (2020) Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial. BMJ 371:m3734. https://doi.org/10.1136/bmj.m3734

Article  PubMed  PubMed Central  Google Scholar 

Chandran S, Tang Q, Sarwal M et al (2017) Polyclonal regulatory T cell therapy for control of inflammation in kidney transplants. Am J Transplant 17:2945–2954. https://doi.org/10.1111/ajt.14415

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brook MO, Hester J, Petchey W et al (2022) Transplantation without overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients. BMJ Open 12:e061864. https://doi.org/10.1136/bmjopen-2022-061864

Article  PubMed  PubMed Central  Google Scholar 

Brook MO, Hennessy C, Hester J et al (2024) Late treatment with autologous expanded regulatory T-cell therapy after alemtuzumab induction is safe and facilitates immunosuppression minimization in living donor renal transplantation. Transplantation. https://doi.org/10.1097/TP.0000000000005065

Article  PubMed  PubMed Central  Google Scholar 

Gedaly R, De Stefano F, Turcios L et al (2019) mTOR inhibitor everolimus in regulatory T cell expansion for clinical application in transplantation. Transplantation 103:705–715. https://doi.org/10.1097/TP.0000000000002495

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dudreuilh C, Jarvis P, Beadle N et al (2023) Can regulatory T cells improve outcomes of sensitised patients after HLA-Ab incompatible renal transplantation: study protocol for the Phase IIa GAMECHANgER-1 trial. BMC Nephrol 24:117. https://doi.org/10.1186/s12882-023-03157-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sagoo P, Ali N, Garg G et al (2011) Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med 3:83ra42. https://doi.org/10.1126/scitranslmed.3002076

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee K, Nguyen V, Lee KM et al (2014) Attenuation of donor-reactive T cells allows effective control of allograft rejection using regulatory T cell therapy. Am J Transplant 14:27–38. https://doi.org/10.1111/ajt.12509

Article  CAS  PubMed  Google Scholar 

Alzhrani A, Bottomley M, Wood K et al (2020) Identification, selection, and expansion of non-gene modified alloantigen-reactive Tregs for clinical therapeutic use. Cell Immunol 357:104214. https://doi.org/10.1016/j.cellimm.2020.104214

Article  CAS  PubMed  Google Scholar 

Guinan EC, Contreras-Ruiz L, Crisalli K et al (2023) Donor antigen-specific regulatory T cell administration to recipients of live donor kidneys: a ONE study consortium pilot trial. Am J Transplant. https://doi.org/10.1016/j.ajt.2023.06.012

Article  PubMed  Google Scholar 

Tang Q, Leung J, Peng Y et al (2022) Selective decrease of donor-reactive T(regs) after liver transplantation limits T(reg) therapy for promoting allograft tolerance in humans. Sci Transl Med 14:eabo2628. https://doi.org/10.1126/scitranslmed.abo2628

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee LM, Zhang H, Lee K et al (2021) A comparison of ex vivo expanded human regulatory T cells using allogeneic stimulated B cells or monocyte-derived dendritic cells. Front Immunol 12:679675. https://doi.org/10.3389/fimmu.2021.679675

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mohseni YR, Saleem A, Tung SL et al (2021) Chimeric antigen receptor-modified human regulatory T cells that constitutively express IL-10 maintain their phenotype and are potently suppressive. Eur J Immunol 51:2522–2530. https://doi.org/10.1002/eji.202048934

Article  CAS  PubMed  PubMed Central  Google Scholar 

MacDonald KG, Hoeppli RE, Huang Q et al (2016) Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest 126:1413–1424. https://doi.org/10.1172/JCI82771

Article  PubMed  PubMed Central  Google Scholar 

Sicard A, Lamarche C, Speck M et al (2020) Donor-specific chimeric antigen receptor Tregs limit rejection in naive but not sensitized allograft recipients. Am J Transplant 20:1562–1573. https://doi.org/10.1111/ajt.15787

Article  CAS  PubMed  Google Scholar 

Schreeb K, Culme-Seymour E, Ridha E et al (2022) Study design: human leukocyte antigen class I molecule A( *)02-chimeric antigen receptor regulatory T cells in renal transplantation. Kidney Int Rep 7:1258–1267. https://doi.org/10.1016/j.ekir.2022.03.030

Article  PubMed  PubMed Central